Does left ventricular hypertrophy affect cognition and brain structural integrity in type 2 diabetes? Study design and rationale of the Diabetes and Dementia (D2) study

BMC Endocrine Disorders

Study Protocol

Vladimir Hachinski¹  Elif I. Ekinci²  Bryan Wai³  Jay Ramchand³  Piyush M. Srivastava³  Louise M. Burrell³  Christopher J. O’Callaghan⁴  Brian Chambers⁵  Emilio Werden⁶  David Darby⁶  Leonid Churilov⁶  Geoff Donnan⁶  Toby Cumming⁶  Carolina Restrepo⁶  Sheila K. Patel⁷  Amy Brodtmann⁸ 

[1] Department of Clinical Neurological Sciences, London Health Sciences Centre, University of Western Ontario, London, Canada;Department of Medicine, University of Melbourne, Austin Health, Level 7, Lance Townsend Building, 145 Studley Road, 3084, Heidelberg, VIC, Australia;Austin Health Endocrine Centre, Heidelberg, VIC, Australia;Department of Medicine, University of Melbourne, Austin Health, Level 7, Lance Townsend Building, 145 Studley Road, 3084, Heidelberg, VIC, Australia;Department of Cardiology, Austin Health, Heidelberg, VIC, Australia;Department of Medicine, University of Melbourne, Austin Health, Level 7, Lance Townsend Building, 145 Studley Road, 3084, Heidelberg, VIC, Australia;Department of Clinical Pharmacology, Austin Health, Heidelberg, VIC, Australia;Department of Medicine, University of Melbourne, Austin Health, Level 7, Lance Townsend Building, 145 Studley Road, 3084, Heidelberg, VIC, Australia;Department of Neurology, Austin Health, Heidelberg, VIC, Australia;The Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Austin Health, 245 Burgundy Street, 3084, Heidelberg, VIC, Australia;The Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Austin Health, 245 Burgundy Street, 3084, Heidelberg, VIC, Australia;Department of Medicine, University of Melbourne, Austin Health, Level 7, Lance Townsend Building, 145 Studley Road, 3084, Heidelberg, VIC, Australia;The Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, Austin Health, 245 Burgundy Street, 3084, Heidelberg, VIC, Australia;Department of Medicine, University of Melbourne, Austin Health, Level 7, Lance Townsend Building, 145 Studley Road, 3084, Heidelberg, VIC, Australia;Department of Neurology, Austin Health, Heidelberg, VIC, Australia;

关键词: Type 2 diabetes mellitus;    Dementia;    Alzheimer’s disease;    Left ventricular hypertrophy;    Dementia;    Cognition;    D2 study;   

DOI  :  10.1186/s12902-017-0173-7

 received in 2017-03-16, accepted in 2017-03-31,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundCognitive impairment is common in type 2 diabetes mellitus, and there is a strong association between type 2 diabetes and Alzheimer’s disease. However, we do not know which type 2 diabetes patients will dement or which biomarkers predict cognitive decline. Left ventricular hypertrophy (LVH) is potentially such a marker. LVH is highly prevalent in type 2 diabetes and is a strong, independent predictor of cardiovascular events. To date, no studies have investigated the association between LVH and cognitive decline in type 2 diabetes. The Diabetes and Dementia (D2) study is designed to establish whether patients with type 2 diabetes and LVH have increased rates of brain atrophy and cognitive decline.MethodsThe D2 study is a single centre, observational, longitudinal case control study that will follow 168 adult patients aged >50 years with type 2 diabetes: 50% with LVH (case) and 50% without LVH (control). It will assess change in cardiovascular risk, brain imaging and neuropsychological testing between two time-points, baseline (0 months) and 24 months. The primary outcome is brain volume change at 24 months. The co-primary outcome is the presence of cognitive decline at 24 months. The secondary outcome is change in left ventricular mass associated with brain atrophy and cognitive decline at 24 months.DiscussionThe D2 study will test the hypothesis that patients with type 2 diabetes and LVH will exhibit greater brain atrophy than those without LVH. An understanding of whether LVH contributes to cognitive decline, and in which patients, will allow us to identify patients at particular risk.Trial registrationAustralian New Zealand Clinical Trials Registry (ACTRN12616000546459), date registered, 28/04/2016

【 授权许可】

CC BY   
© The Author(s). 2017